Connect with us

Sponsored Content

Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market

Joe Samuel



Technology has evolved over the years, and so have online websites and apps. Growing food delivery apps are the newest trend, expanding revenue generation in the food-service industry by 22% or more. And this new trend has created an even greater opportunity beyond food delivery alone!

Uber Eats has about 20% of the market, while GrubHub, including Seamless and Eat24, has 52%. In its latest funding effort, DoorDash raised $250 million after the five-year-old San Francisco-based startup raised $535 million in March. Furthermore, DoorDash, which competes with GrubHub (GRUB), Uber Eats, and Postmates, has raised nearly $1 billion overall.

Stock Price

CEO of Uber Dara Khosrowshahi has said that Uber Eats is growing at 200% per year and has a $6 billion run rate, meaning that it’s on track to book $6 billion over the next 12 months given current rates. She said, “Going forward, we’re deliberately investing in the future of our platform: big bets like Uber Eats…”

Going Global – The Real Opportunity For Investors

Chinese investor and WeChat owner Tencent has joined a global lineup of investors seeking to write the biggest check in India’s food-technology sector for Swiggy. The online food-delivery platform has held discussions with a host of investors to raise $500-700 million, a significant portion of which Tencent wants to contribute, according to people familiar with the talks.

The investment could value Swiggy at $2.5-3 billion. Swiggy has also been in talks with Japan’s SoftBank for a sizeable investment since November, according to reports.

Another app called Rappi is a Colombian on-demand delivery startup that has brought in a new round of funding at a valuation north of $1 billion, as first reported by Axios and confirmed to TechCrunch by a source close to the company. DST Global led the more than $200 million in financing with participation from Andreessen Horowitz and Sequoia, all of which were existing investors in the company.

But Here’s The Problem: Most Companies Are Private

Private companies are mostly driving these billions and trillions of dollars that are being poured into this new On-Demand Economy. The average retail investor has little opportunity to take advantage of it, especially considering this idea of global expansion that could turbo-charge industry growth.

ParcelPal (PTNYF) (PKG) Is The One Company That’s Already Breaking Into The Global On-Demand Industry At A Rapid Pace

The opportunity that ParcelPal (PTNYF) (PKG) may be presenting now draws comparisons to the way early investors had an opportunity with companies like Uber and GrubHub (GRUB) before they went mainstream in the US. GrubHub priced its initial public offering at $26 per share and now trades nearly 5x that price just as this market is beginning to heat up!

Latest News:

ParcelPal Has Gross Profits of $802,035 In Fiscal 2018

The difference withParcelPal (PTNYF) (PKG) is that it is going directly after the international markets that have very limited access to technology like this right now. In fact, the major players in the industry are just beginning to get their feet wet with beta testing; they aren’t even full speed yet.

ParcelPal Stock Logo

ParcelPal (PTNYF) (PKG) created an on-demand marketplace where customers can shop for anything from food to clothes. There is no more waiting in line for lunch or rushing to the store after work to grab your clothes. With ParcelPal on-demand, customers simply shop from the app, choose the items they want, and pay.

A ParcelPal (PTNYF) (PKG) courier will accept the request and pick up and drop off the items to wherever customers want within one hour.

ParcelPal (PTNYF) (PKG) Gets A “Little Help” From An E-commerce Company: Amazon!

It’s true that new markets are difficult to enter, especially if it is a brand new way of doing business, such as the on-demand economy. But unlike the Ubers and Postmates in their early years, ParcelPal (PTNYF) (PKG) has already aligned with one of the largest online juggernauts in the history of the modern world.

ParcelPal (PTNYF) (PKG) has engaged in a work order contract with Inc. to fulfill package delivery amazon stock priceon behalf of Amazon to residents in Metro Vancouver, British Columbia, Canada. ParcelPal (PTNYF) (PKG) has already seen exceptional growth in this division of the company since launch, growing over 115% week over week, delivering approximately 150,000 packages since mid-November.

The company is currently maintaining an average of 99%+ delivery success rate and is delivering thousands of packages daily on behalf of Amazon. The contract signed involves delivering for Amazon “Core” services. This entails delivering Amazon merchandise to Greater Vancouver residents.

The company is already aiming to expand on both the existing “Core” business and Amazon Prime services!

Entry Into Key Verticals

Something that is beginning to set ParcelPal (PTNYF) (PKG) apart from its immediate competition is its diversification strategy. Not only is the company working with the likes of Amazon, but it is also entering into key verticals that are seeing an increase in rapid demand. Right now, ParcelPal has built relationships with businesses in both alcohol and cannabis.

We don’t have to go into the deep details of these booming industries, but it is vital to understand that the evolution from brick-and-mortar to on-demand delivery could be setting the stage for a major economic boom.

While consumers are becoming more comfortable with using smartphones and computers to buy groceries, they are also increasingly using the same technology to help them skip trips to the liquor store, according to data from the e-commerce analytics firm, Slice Intelligence.

cannabis delivery alcohol delivery

Online alcohol sales of beer, liquor, and wine grew 32.7% in 2017, according to Slice. By far, the most popular kind of adult beverage bought on the Web is wine, which represented more than 65% of online alcohol sales during the 25-month period from Jan. 1, 2016 to Jan. 31, 2018, according to Slice. Spirits follow that, at 21.2%, and beer at 13.8%.

ParcelPal (PTNYF) (PKG) Welcomes Ontario MP Ben Lobb to the Advisory Board of Directors

“While e-commerce in the alcoholic beverage space is still immature, we are starting to see the shape of a robust category,” says Ken Cassar, principal analyst for Slice. “It makes sense that wine would lead all subcategories within alcoholic beverages, due to the relatively high value of scarce wine. Ultimately, though, beer will likely win as grocers figure out how to manage through complicated laws that vary by local jurisdiction.”

This is just one slice of ParcelPal (PTNYF) (PKG)’s directive to take on “sin-dustries” (sin industries like alcohol, tobacco, and marijuana). With the budding market in Canada alone proposed to reach somewhere in the billions of dollars, cannabis presents a more near-term opportunity for ParcelPal.

According to the latest projections from San Francisco-based ArcView Group, a marijuana research, and investment firm, in partnership with Boulder-based BDS Analytics, a cannabis-focused market researcher, the Canadian legal cannabis sector is estimated to generate $1.3 billion in 2018. By 2022, the forecast is even more robust—$5.4 billion for both the medical and recreational markets.

ParcelPal Strategically Advances Into Marijuana Space Through Acquisition and Partnership with TokeIt Technologies

ParcelPal (PTNYF) (PKG) has entered into a definitive agreement for partial acquisition and exclusive partnership with marijuana seed-to-sale provider and online ordering system, TokeIt Technologies, Inc.

A cannabis focus will give all TokeIt-engaged licensed dispensaries the ability to offer their consumers the opportunity to order marijuana directly through the ParcelPal or TokeIt applications and have it delivered in an hour or less. This partnership offers ParcelPal access to thousands of customers in neighborhoods throughout Vancouver.

ParcelPal to Launch Cannabis Delivery on April 15th

The deal gives ParcelPal access to more than 15,000 customers on the TokeIt platform and nearly 50 dispensaries partnered with TokeIt with which ParcelPal currently operates. According to the company, the average dispensary on the TokeIt Platform produces more than $250,000 per month.

More Deals Signal Additional Market Opportunities

As the marijuana industry evolves, new opportunities have come about.  One of the bigger deals closed in 2019 was between ParcelPal (PTNYF) (PKG) and Yield Growth! The deals forms an alliance between the two companies for same-day and on-demand delivery, sale, of hemp-based cosmetics from Yield Growth’s subsidiary Urban Juve in Canada.

The New Market Reach Could Be Unparalleled

Urban Juve hemp products are currently sold in over 90 locations including well known pharmacy chains across North America, with a plan to expand that to 130 retail outlets in the near future.

Customers will be able to track their purchase in real time and have their product delivered to any location they specify. As time and regulations allow, ParcelPal’s cannabis network will continue to grow, with the goal of capturing a major piece of Canada’s $5.2 B legal cannabis market.

“ParcelPal is thrilled to be working an innovative company such as The Yield Growth’s Corp, which is addressing one of the fastest-growing subsegments of the $4.2 trillion wellness market with unique derived and cannabis infused products. This marks a milestone at ParcelPal, launching a new vertical with substantial growth potential. It’s also a unique opportunity to be at the forefront of an exciting new industry with our unique logistics solutions.”

Kelly Abbott, President and CEO, ParcelPal Technologies

New Opportunities Arise With Leadership

The company welcomed Ontario MP Parm Gill as an advisor to the Board of Directors.

Parm Gill is the current Member of Provincial Parliament for Milton. Prior to his work in public service, Parm was involved in several family businesses in the manufacturing and hospitality industries. Parm studied at the Ivey School of Business at Western University, earning his Master of Business Administration degree.

Before being elected to the Ontario Legislature in 2018, Parm was the Federal Member of Parliament for Brampton-Springdale from 2011-2015.

While serving as the MP in the Canadian House of Commons, Parm was appointed as the Parliamentary Secretary to the Minister of Veteran Affairs, and later, the Minister of International Trade. Throughout his tenure, Parm was a member of many committees including the Standing Committee of Public Safety and National Security, Health, Canadian Heritage, Veterans Affairs, and International Trade

An Industry Already Built For Big Buyouts

Amazon is often named as a potential suitor for a number of tech-based companies, especially for food delivery, where the Whole Foods acquisition might have been just the tip of the iceberg.  In 2017, a study from the Food Marketing Institute (FMI) and The Nielsen Co. predicted that, by 2025, as many as 70% of U.S. consumers will be buying groceries online, and those purchases will total more than $100 billion. An update of the FMI/Nielsen report published last month, however, moved that timeframe up by three years to 2022.

FMI and Nielsen cited big acquisitions as key drivers accelerating the pace of change in the online food market.

The report calls out the $13.7 billion purchase of Whole Foods by Inc. in 2017, the 2016 acquisition of by Walmart Inc. for $3.3 billion, the purchase of meal-kit delivery company Plated by Albertsons Cos. last fall (terms were not disclosed), and the acquisition of Shipt Inc. by Target late in 2017 for $550 million.

Currently, the FMI/Nielsen report says that 49% of U.S. consumers shop for consumer packaged goods (CPG)—the kinds of products typically found in grocery stores—online. And it’s not just Millennials who are shopping for food online. The report says that 61% of Millennials, 55% of Generation X, 41% of Baby Boomers, and 39% of those born before the Baby Boom reported having recently purchased a CPG product online.

These Are Just The Numbers From The United States!

The purpose of mentioning big figures like these isn’t to explain how big the US market for on-demand delivery has become; it’s to show how big it could become across other markets. With big buyouts from some of the major players in the business like WalMart, Albertsons, and Amazon, this industry is already built for big buyouts.

The Market Boom is Coming

The M&A strategy shows that this market isn’t one to ignore right now, and the real market boom may not even be here yet. Between 2016 and 2017, the amount that users are spending for ordering/booking on-demand service apps has only risen.

According to the data collected by the National Technology Readiness Survey in the U.S., it was estimated that total spending on the on-demand mobile app services would increase from $48 billion n 2016 to $75.7 billion in 2017—an increase amounting to 58%.


The segments of the on-demand startup market that have witnessed maximum growth, consist of housing items from $5 billion in ‘16 to $10.6 billion in ‘17; transportation, which moved from $6.8 billion in ‘16 to $14.2 billion in ‘17; and, lastly, the food delivery category, which shifted to $8.2 billion in 2017 from $3.9 billion in 2016.

Seeing this growing spending number, Rockbridge estimated that the number of on-demand mobile app startup consumers would reach 56 million by the end of 2018 and 93 million by the time we hit 2022.

The rise in awareness has brought in a rise in the perceived advantage that users are getting by using the on-demand services. The main advantages include the ability to find service online on an app (70%), the benefit of paying and tracking the progress of the delivery person on the app (62%), and, lastly, the perk that comes with being connected with another person in place of a business (52%).

Limited Options In the Public Markets Give Rise To Targeted Opportunities For Investors

It’s true that this market is exploding right in front of our eyes, but just as with the boom that the “Over The Top” entertainment industry saw with the advent of Netflix, right now there are a limited number of offerings available for investors to look at.

It is undeniable how on-demand is changing the world around us as we know it. No matter which business segment you belong to, chances are that someone in your industry will be thinking about investing in the on-demand market.


This un-altering demand for the on-demand services is not just the truth of the present day; the future has a similar story to share. The future of on-demand lies in a number of categories. According to a PwC report, the on-demand economy revenue, which was $14 billion in 2014, will reach $335 billion by the time we reach 2025.

ParcelPal (PTNYF) (PKG) could already be grabbing first mover advantage when it comes to taking on the global arena. Surely, there are already billions being invested in the startups of tomorrow, and as these companies “prepare,” ParcelPal is already entering into key verticals, aligning with major companies like Amazon, while also expanding the technology of their application to deliver a seamless customer experience for a country that is just beginning to find out what on-demand services are!

With the feverish pitch that the global on-demand industry is set to see, can you afford to miss out on something for which early adopters are already earmarking billions of dollars for massive future growth?

ParcelPal (PTNYF) (PKG) News:

April 4, 2019 – ParcelPal (PTNYF) (PKG) Announces Call-in Details for Quarterly Reporting Call to Take Place on May 17, 2019

March 21, 2019 – ParcelPal (PTNYF) (PKG) Achieves Milestone of Two Million Deliveries

March 14, 2019 – ParcelPal (PTNYF) (PKG) Signs Cannabis Distribution Agreement With Kiaro

Feb 27, 2019 – ParcelPal (PTNYF) (PKG) Welcomes Brian Storseth to the Board of Directors and Acting Chairman

Jan 29, 2019 – ParcelPal (PTNYF) (PKG) Announces Strategic Partnership With MADD Canada to Stop Impaired Driving

Jan 17, 2019 – ParcelPal (PTNYF) (PKG) Bringing Augmented Reality to Platform With NexTech AR Integration Deal

 Jan 9, 2019 – ParcelPal (PTNYF) (PKG.CN) CEO Kelly Abbott Provides a Corporate Update

Disclaimer: MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to June 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to July 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Click Here For Full Disclaimer

Continue Reading

Biotechnology Subscribers WIN BIG!

Jon Phillip



stock price WINNING

We owe you a BIG congratulations. The whole point of is to bring you important information, first. Sure we send emails out every day on top trending articles and news but we also bring periodic reports on certain companies.

Earlier this year we brought you a full report on a company, PharmaCyte Biotech (PMCB).

Since that report, we’ve watched as PharmaCyte evolved into what it has become today: a biotech powerhouse on the verge of presenting its treatment to the FDA!

Stock Price Subscribers Saw The Full PMCB 90%+ Breakout From August – December; Congratulations! Click Here to Read Our Original Report

This is a great thing for subscribers and we’ve got more featured reports coming! How do you get these reports first?

STEP 1: Make Sure Our Email Address Is In Your Whitelist Address Book So Nothing Gets Lost In Spam

STEP 2:Take Out Your Cell Phone And Text “STOCKPRICE” to 63566. Even If You Miss An Email, We Send Out Updates Directly To Your Cell Phone In Real Time

Again, congratulations to everyone and make sure you stay tuned for our next Stock Price Exclusive Report!

Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Continue Reading


Are These 3 Biotech Stocks On Your Watch List in October?

A. Lawrence



Small-Cap Biotechnology Stocks Are Starting To Outperform Blue-Chips

Biotechnology stocks are currently performing well hitting new milestones in terms of share performance. Despite growing concerns of increased regulation on domestic pricing established biotechnology companies with establishing market position will continue to thrive.

Small-cap stocks can be outstanding growth vehicles for the risk-averse crowd. On balance, stocks with market caps below $2 billion have trounced the broader markets over the past two decades. The downside is that small-cap stocks tend to be on the volatile side.

But if you can handle volatility, it may be time to turn your attention to this area of the market. Here are three biotech stocks to watch that have promising potential in the near term.

GT Biopharma (GTBP)

Whenever you think of biotechnology or biopharma stocks, what comes to mind? For most, it’s the fact that the smaller companies tend to go after major breakthrough therapies. The general hopes are that the company could get bought out by a larger company or score a key win from the FDA. But what needs to be in place is the right framework and a general proof of concept.

biotechnology stocks to buy now 2019

Needless to say, small-cap companies strive to achieve this. New findings may suggest GT Biopharma (GTBP) therapies could eliminate HIV infected cells. You read that right. The company’s therapy showed that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could actually be eliminated (Click For More Details On This).

The Problem: Despite the use of anti-retroviral drugs, infected individuals retain reservoirs of latent HIV-infected cells that, upon cessation of antiretroviral drug therapy, can reactivate and re-establish an active HIV infection. For curative therapy, the destruction of these latent HIV infected cells must take place.

At the University of Minnesota GT Biopharma (GTBP) presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg and discussed its design of an HIV-TriKE™ containing an antigen-binding fragment from a broadly-neutralizing antibody targeting the HIV-Env protein. The HIV-TriKE™ is designed to target HIV while redirecting NK cell killing specifically to actively replicating HIV infected cells.

The TriKE™ technology is able to be extended to the treatment of infectious disease, and is able to kill HIV in the reservoir.”

Anthony Cataldo , the Chairman and Chief Executive Officer of GT Biopharma

BioDelivery Sciences International (BDSI)

BioDelivery Sciences International Inc. (NASDAQ:BDSI) has been gaining momentum so far in October, with a jump of 12%. The company in its most recent quarter beat analysts’ estimates of $25.30 million in revenue and posted revenue of around $29.68.

The company recently announced that from October 1st, a PBM will commence provision of enhanced access of patients to BELBUCA CII and Symproic tablets. With this, around 14 million patients to gain access to BELBUCA as a buprenorphine product in their coverage plans and Symproic as the preferable exclusive product.

biotech stock to buy 2019

BELBUCA has approval in the US for treatment of severe pain that requires constant long-term opioid treatment for which other treatment alternatives are inadequate. This Schedule III drug presents much potential for the company considering it is not prone to abuse.

Agile Therapeutics (AGRX)

Agile Therapeutics Inc. (NASDAQ:AGRX) is also another biotechnology stock to watch that has some promising developments. Recently the company indicated that it was in the final stages of a clinical study for its lead product Twirla.

The company has committed all its resources in the development of the product. Agile resubmitted Twirla for New Drug Application this year with the advisory committee expected to meet at the end of this month and then followed by PDUFA next month.

Twirla is a birth control contraceptive patch that once it receives approval will make it easier to take relative to the daily contraceptive pill. Twirla is using two active ingredients popular in contraceptives. The drug faces competition from Ortho Evra and Xulane but it will still manage to cut a share of the market from the established products. If the drug receives approval then it will be a huge development for investors. Twirla presents massive potential which is why Agile is among the Biotech stocks to watch.

top biotechnology stocks to watch today

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).  Click Here For Full Disclaimer.

Continue Reading


Biotechnology Stocks To Watch In October

A. Lawrence



Biotechnology stocks are some of the hottest commodities traded on the market at this point in time. The biotechnology industry is undergoing a significant change and it is coming from the regenerative medicine field. A lot of players in this field are just starting out and are making their impact known.

Some of the best penny stocks to buy come from the biotechnology sector as well. Companies in this sector release a lot of penny stock news which encourages fast and frequent price action. Here are some small-cap biotech stocks shaping the healthcare industry through regenerative medicine:

Biotechnology Stocks To Watch#1: Sernova Corp. (SVA.V) (SEOVF)

One healthcare company that is primarily focused on regenerative medicine therapeutics is Sernova Corp. (SVA.V) (SEOVF). In order to develop its treatments, the company developed a technology known as Cell Pouch. The Cell Pouch generates proteins, hormones, or other necessities and then releases them into the bloodstream to treat diseases. The technology aims to replace the act of daily administering drugs to combat diseases.

\\\FREE REPORT\\\ A Breakthrough in Biotech May Put Investors at an Advantage

One of the primary diseases that Sernova is aiming to treat is diabetes. The biggest problem with current insulin treatments is that it does not produce tight control of a patient’s glucose levels. However, through Cell Pouch cell transplantation, long-term and targeted treatments for maintaining glucose levels to treat diabetes is possible.

Sernova has a growing portfolio of drugs in its clinical pipeline. The company has 3 treatments for diabetes undergoing the clinical-stage process. 2 are preclinical and 1 for human donor islets is in Phase 1/2. Furthermore, the company has drugs in the pipeline that are designed to treat hemophilia A and thyroid disease.

Biotechnology Stocks To Watch #2: Vertex Pharmaceuticals Incorporated (VRTX)

One of the largest biotechnology companies in the healthcare sector is known as Vertex Pharmaceuticals Incorporated (VRTX Stock Report). Vertex Pharmaceuticals currently has 3 approved medicines to treat cystic fibrosis. In addition, Vertex bought out Semma Therapeutics for $950 million. This acquisition represents an overall trend for big pharma to buy out lucrative smaller pharma.

Semma Therapeutics produces regenerative medicine treatments to treat type 1 diabetes which affects millions of people. Semma’s line of attack is to change the distribution method of diabetes treatments from daily dosages to stem cell transplants. This is very similar to Sernova so it’s no surprise that attention on companies targeting this type of technology are getting scooped up right now. Who will be next?

Biotechnology Stocks To Watch #3: Athersys Inc. (ATHX)

Another regenerative medicine company called Athersys Inc. (ATHX Stock Report) focuses on treating neurological, inflammaroty, and cardiovascular diseases. In order to create solutions to these diseases, the company utilizes its MultiStem therapy platform. It has been undergoing clinical trial tests and has started its Phase 3 trial.

The company is expected to present at the 2019 Cell and Gene Meeting on the Mesa. In the presentation, CEO Dr. Gil Van Bokkelen will discuss Athersys’ Phase 3 trial for its MultiStem cell therapy. In addition, the company will discuss MultiStem in more depth as well as the company’s mission.

Biotechnology Stocks To Watch #4: Mesoblast Limited (MESO)

One of the companies on this list creates product candidates based on mesenchymal lineage adult stem cells. Mesoblast Limited (MESO Stock Report) creates products for difficult-to-treat diseases. The company has 3 products in Phase 3 trials including Revascor (advanced heart failure) and remestemcel-L (acute graft versus host disease).

biotech penny stocks to watch october 2019

Mesoblast recently announced that it has entered a strategic partnership with Grünenthal.  Grünenthal has lead the healthcare field focused on pain management. This partnership targets sales & creation of treatments for chronic low back pain. Mesoblast will receive $150 million to launch MPC-06-ID, a Phase 3 cell therapy for low back pain.

biotechnology stocks to watch now
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!

Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (


Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact